期刊文献+

New advances in radiomics of gastrointestinal stromal tumors 被引量:4

下载PDF
导出
摘要 Gastrointestinal stromal tumors(GISTs)are uncommon neoplasms of the gastrointestinal tract with peculiar clinical,genetic,and imaging characteristics.Preoperative knowledge of risk stratification and mutational status is crucial to guide the appropriate patients’treatment.Predicting the clinical behavior and biological aggressiveness of GISTs based on conventional computed tomography(CT)and magnetic resonance imaging(MRI)evaluation is challenging,unless the lesions have already metastasized at the time of diagnosis.Radiomics is emerging as a promising tool for the quantification of lesion heterogeneity on radiological images,extracting additional data that cannot be assessed by visual analysis.Radiomics applications have been explored for the differential diagnosis of GISTs from other gastrointestinal neoplasms,risk stratification and prediction of prognosis after surgical resection,and evaluation of mutational status in GISTs.The published researches on GISTs radiomics have obtained excellent performance of derived radiomics models on CT and MRI.However,lack of standardization and differences in study methodology challenge the application of radiomics in clinical practice.The purpose of this review is to describe the new advances of radiomics applied to CT and MRI for the evaluation of gastrointestinal stromal tumors,discuss the potential clinical applications that may impact patients’management,report limitations of current radiomics studies,and future directions.
出处 《World Journal of Gastroenterology》 SCIE CAS 2020年第32期4729-4738,共10页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献1

二级参考文献44

  • 1Miettinen M, Lasota J. Histopathology of gastrointestinal stromaltumor. J Surg Oncol 2011; 104: 865-873 [PMID: 22069171 DOI:10.1002/jso.21945].
  • 2Rubin BP. Gastrointestinal stromal tumours: an update.Histopathology 2006; 48: 83-96 [PMID: 16359540].
  • 3Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL,Zewe JP, Wozniak A, Mehalek KR, Korzeniewski N, SeneviratneDS, Sch-ffski P, Debiec-Rychter M, DeCaprio JA, Duensing A.The DREAM complex mediates GIST cell quiescence and is anovel therapeutic target to enhance imatinib-induced apoptosis.Cancer Res 2013; 73: 5120-5129 [PMID: 23786773 DOI:10.1158/0008-5472.CAN-13-0579].
  • 4Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, LongleyBJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B,Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors:A consensus approach. Hum Pathol 2002; 33: 459-465 [PMID:12094370].
  • 5Miettinen M, Lasota J. Gastrointestinal stromal tumors: reviewon morphology, molecular pathology, prognosis, and differentialdiagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478 [PMID:17090188].
  • 6Joensuu H. Predicting recurrence-free survival after surgery forGIST. Lancet Oncol 2009; 10: 1025 [PMID: 19793677 DOI:10.1016/S1470-2045(09)70267-0].
  • 7Huang H, Liu YX, Zhan ZL, Liang H, Wang P, Ren XB. Differentsites and prognoses of gastrointestinal stromal tumors of thestomach: report of 187 cases. World J Surg 2010; 34: 1523-1533[PMID: 20145924 DOI: 10.1007/s00268-010-0463-y].
  • 8Goh BK, Chow PK, Yap WM, Kesavan SM, Song IC, PaulPG, Ooi BS, Chung YF, Wong WK. Which is the optimal riskstratification system for surgically treated localized primaryGIST- Comparison of three contemporary prognostic criteria in171 tumors and a proposal for a modified Armed Forces Instituteof Pathology risk criteria. Ann Surg Oncol 2008; 15: 2153-2163[PMID: 18546045 DOI: 10.1245/s10434-008-9969-z].
  • 9Wong NA. Gastrointestinal stromal tumours-an update forhistopathologists. Histopathology 2011; 59: 807-821 [PMID:21668468 DOI: 10.1111/j.1365-2559.2011.03812.x].
  • 10Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathologyand prognosis at different sites. Semin Diagn Pathol 2006; 23:70-83 [PMID: 17193820].

共引文献14

同被引文献29

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部